ArticleMicrobiology spectrum2015
Fungal Biofilms: In Vivo Models for Discovery of Anti-Biofilm Drugs.
Article in Microbiology spectrum, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 58 citations in OpenAlex.
- Effects of Antimicrobial Photodynamic Therapy Mediated by Free Curcumin and Curcumin-Associated Superparamagnetic Iron Oxide Nanoparticles onACS omega · 2026Article
- Bridging the "Valley of Death" in Antifungal Therapy: Next-Generation Biomimetic and Exosome-Inspired Nanocarriers for Invasive Candidiasis.Journal of fungi (Basel, Switzerland) · 2026Review
- Antibiofilm activity of terbinafine, itraconazole and their combination against Sporothrix brasiliensis yeast-like form's biofilms.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Rezafungin for Salvage or Consolidation Therapy of Invasive Fungal Disease: Experience in Real-World Clinical Practice.Mycoses · 2026Article
- StudyingPharmaceuticals (Basel, Switzerland) · 2025Review
- Rezafungin Utilisation in Real Life-FungiScope Results From Europe and the United States.Mycoses · 2025Article
- Antimicrobial Resistance in Oral Healthcare: A Growing Concern in Dentistry.Dentistry journal · 2025Review
- Next-generation antifungal drugs: Mechanisms, efficacy, and clinical prospects.Acta pharmaceutica Sinica. B · 2025Review
- The Hidden Fortress: A Comprehensive Review of Fungal Biofilms with Emphasis onJournal of fungi (Basel, Switzerland) · 2025Review
- Extracellular vesicles from bacteria and fungi: mechanistic insights and implications for urinary tract infections.Extracellular vesicles and circulating nucleic acids · 2025Review
- Biochanin A Inhibits the Growth and Biofilm ofPharmaceuticals (Basel, Switzerland) · 2024Article
- Emerging Antifungal Targets and Strategies.International journal of molecular sciences · 2022Review
- Nanotechnology in combating biofilm: A smart and promising therapeutic strategy.Frontiers in microbiology · 2022Review
- Characterization ofFrontiers in molecular biosciences · 2022Article
- Fungal Biofilms as a Valuable Target for the Discovery of Natural Products That Cope with the Resistance of Medically Important Fungi-Latest Findings.Antibiotics (Basel, Switzerland) · 2021Review
- Oral Candidiasis: A Disease of Opportunity.Journal of fungi (Basel, Switzerland) · 2020Review
- Innate Inspiration: Antifungal Peptides and Other Immunotherapeutics From the Host Immune Response.Frontiers in immunology · 2020Review
- Digital Design of a Universal Rat Intraoral Device for Therapeutic Evaluation of a Topical Formulation againstInfection and immunity · 2019Article
- Delineating the Biofilm Inhibition Mechanisms of Phenolic and Aldehydic Terpenes againstACS omega · 2019Article
- Testing Anti-Biofilm Polymeric Surfaces: Where to Start?International journal of molecular sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
During infection, fungi frequently transition to a biofilm lifestyle, proliferating as communities of surface-adherent aggregates of cells. Phenotypically, cells in a biofilm are distinct from free-floating cells. Their high tolerance of antifungals and ability to withstand host defenses are two characteristics that foster resilience. Biofilm infections are particularly difficult to eradicate, and most available antifungals have minimal activity. Therefore, the discovery of novel compounds and innovative strategies to treat fungal biofilms is of great interest. Although many fungi have been observed to form biofilms, the most well-studied is Candida albicans. Animal models have been developed to simulate common Candida device-associated infections, including those involving vascular catheters, dentures, urinary catheters, and subcutaneous implants. Models have also reproduced the most common mucosal biofilm infections: oropharyngeal and vaginal candidiasis. These models incorporate the anatomical site, immune components, and fluid dynamics of clinical niches and have been instrumental in the study of drug resistance and investigation of novel therapies. This chapter describes the significance of fungal biofilm infections, the animal models developed for biofilm study, and how these models have contributed to the development of new strategies for the eradication of fungal biofilm infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.